A Phase II Study of Topotecan in Patients With Anaplastic Oligodendroglioma or Anaplastic Mixed Oligoastrocytoma

NCIC Clinical Trials Group11 sites in 1 country17 target enrollmentDecember 8, 1997

ConditionsBrain and Central Nervous System Tumors

Drugstopotecan hydrochloride

Overview

Phase: Phase 2
Intervention: Not specified
Conditions: Brain and Central Nervous System Tumors
Sponsor: NCIC Clinical Trials Group
Enrollment: 17
Locations: 11
Status: Completed
Last Updated: 6 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase II trial to study the effectiveness of topotecan in treating patients with recurrent brain tumor.

Detailed Description

OBJECTIVES: I. Determine the efficacy of topotecan in patients with recurrent anaplastic oligodendroglioma or anaplastic mixed oligoastrocytoma. II. Determine the qualitative and quantitative toxicity of topotecan in this patient population on this schedule. OUTLINE: This is a multicenter study. Patients receive intravenous topotecan over 30 minutes daily for 5 days every 3 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients will be followed every 3 months until death. PROJECTED ACCRUAL: Up to 30 evaluable patients will be accrued within 2-3 years.

Registry

clinicaltrials.gov

Start Date

December 8, 1997

End Date

December 21, 2009

Last Updated

6 years ago

Study Type

Interventional

Study Design

Single Group